GH1 and metabolic dysfunction-associated steatohepatitis: After 24 months, ALT and AST were significantly lower in those receiving GH compared to the control group; sustained reductions in ALT and AST over 24 months were also reported in a subgroup of 13 individuals with GHD and NASH who were treated with GH [67].